{
    "id": 14634,
    "fullName": "CSF3R W791*",
    "impact": "nonsense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CSF3R W791* results in a premature truncation of the Csf3r protein at amino acid 791 of 836 (UniProt.org). W791* results in increased cell surface Csf3r expression, hypersensitivity to G-CSF stimulation, elevated Stat5 activation, and is transforming in cell culture (PMID: 28439110).",
            "references": [
                {
                    "id": 13514,
                    "pubMedId": 28439110,
                    "title": "Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28439110"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1441,
        "geneSymbol": "CSF3R",
        "terms": [
            "CSF3R",
            "CD114",
            "GCSFR",
            "SCN7"
        ]
    },
    "variant": "W791*",
    "createDate": "12/01/2015",
    "updateDate": "12/13/2019",
    "referenceTranscriptCoordinates": {
        "id": 121654,
        "transcript": "NM_000760",
        "gDna": "chr1:g.36466496C>T",
        "cDna": "c.2372G>A",
        "protein": "p.W791*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19744,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells expressing CSF3R W791* were sensitive to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell survival (PMID: 28031554).",
            "molecularProfile": {
                "id": 14890,
                "profileName": "CSF3R W791*"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19746,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells expressing CSF3R W791* demonstrated resistance to treatment with Sprycel (dasatinib) in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 14890,
                "profileName": "CSF3R W791*"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19736,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells expressing CSF3R W791** were sensitive to treatment with AZD1480 in culture, demonstrating decreased cell survival (PMID: 28031554).",
            "molecularProfile": {
                "id": 14890,
                "profileName": "CSF3R W791*"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19739,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell survival (PMID: 28031554).",
            "molecularProfile": {
                "id": 34474,
                "profileName": "CSF3R T618I CSF3R W791*"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19738,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with AZD1480 in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 34474,
                "profileName": "CSF3R T618I CSF3R W791*"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19740,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with Sprycel (dasatinib) in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 34474,
                "profileName": "CSF3R T618I CSF3R W791*"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14890,
            "profileName": "CSF3R W791*",
            "profileTreatmentApproaches": [
                {
                    "id": 19896,
                    "name": "JAK Inhibitor (Pan) - ATP competitive",
                    "profileName": "CSF3R W791*"
                }
            ]
        },
        {
            "id": 34474,
            "profileName": "CSF3R T618I CSF3R W791*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 121654,
            "transcript": "NM_000760",
            "gDna": "chr1:g.36466496C>T",
            "cDna": "c.2372G>A",
            "protein": "p.W791*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}